诊断为前列腺癌的男性存在与心脑血管代谢性疾病相关的竞争性发病率和死亡风险，原因是他们被诊断时已处于晚期年龄，患有预先存在的风险因素，并接受针对雄激素受体（AR）的系统性治疗。专家小组强调了临床中评估心脑血管代谢风险的重要性，并提议使用共识范式评估重要风险。然而，在与前列腺癌患者开展全面心脑代谢护理实施方面存在实证研究的差距。 本研究是关于前列腺癌患者的回顾性、描述性研究，研究对象是在MD Anderson癌症中心的健康心脏计划中进行转诊和评估的患者，该计划旨在减轻前列腺癌患者的心脑代谢风险。患者由心脏病专家和运动生理学家进行评估和管理心脑代谢风险因素，包括血压、胆固醇、血糖、吸烟和冠状动脉疾病，同时由医学肿瘤学家管理其癌症治疗。 从2018年12月至2021年10月，健康心脏计划共招募了55名前列腺癌患者，其中35名患者出现了生化学复发、局部区域复发或远处转移，而所有患者至少接受了一次黄体释放激素（LHRH）类似物的治疗。93％的男性超重或肥胖，51％的男性根据汇总队列方程在10年内患动脉粥样硬化性心脑血管疾病的中度或高风险。大多数男性存在两种或更多心脑代谢疾病的重叠（84％），25％的男性存在至少4种心脑代谢疾病的重叠。尽管队列中存在未经控制的高血压和高脂血症（分别为45％和26％），但只有29％的男性在诊所进行了随访。 前列腺癌患者存在与心脑代谢风险因素相关的高负担。在三级癌症中心中，实施了健康心脏计划以解决这个问题，但该计划的效用受到了随访不佳的限制，可能是由于外部心脑代谢护理和不便的预约安排、就诊时缺乏心脑代谢实验室以及远程医疗就诊等原因所致。 © 2023. BioMed Central Ltd., part of Springer Nature.

Men diagnosed with prostate cancer are at risk for competing morbidity and mortality due to cardiometabolic disease given their advanced age at diagnosis, high prevalence of pre-existing risk factors, and receipt of systemic therapy that targets the androgen receptor (AR). Expert panels have stressed the importance of cardiometabolic risk assessment in the clinic and proposed evaluating key risks using consensus paradigms. Yet, there is a gap in real-world evidence for implementation of comprehensive cardiometabolic care for men with prostate cancer.This is a retrospective, descriptive study of patients with prostate cancer who were referred and evaluated in the Healthy Heart Program at MD Anderson Cancer Center, which was established to mitigate cardiometabolic risks in men with prostate cancer. Patients were seen by a cardiologist and exercise physiologist to evaluate and manage cardiometabolic risk factors, including blood pressure, cholesterol, blood glucose, tobacco use, and coronary artery disease, concurrent with management of their cancer by a medical oncologist.From December 2018 through October 2021, the Healthy Heart Program enrolled 55 men with prostate cancer, out of which 35 had biochemical, locoregional recurrence or distant metastases, while all received at least a single dose of a luteinizing hormone-releasing hormone (LHRH) analog. Ninety-three percent of men were overweight or obese, and 51% had an intermediate or high risk of atherosclerotic cardiovascular disease at 10 years based on the pooled cohort equation. Most men had an overlap of two or more cardiometabolic diseases (84%), and 25% had an overlap of at least 4 cardiometabolic diseases. Although uncontrolled hypertension and hyperlipidemia were common among the cohort (45% and 26%, respectively), only 29% of men followed up with the clinic.Men with prostate cancer have a high burden of concurrent cardiometabolic risk factors. At a tertiary cancer center, the Healthy Heart Program was implemented to address this need, yet the utility of the program was limited by poor follow-up possibly due to outside cardiometabolic care and inconvenient appointment logistics, a lack of cardiometabolic labs at the time of visits, and telemedicine visits.© 2023. BioMed Central Ltd., part of Springer Nature.